SCD-044 for Eczema
(SOLARES-AD-1 Trial)

Recruiting in Palo Alto (17 mi)

+84 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Sun Pharmaceutical Industries Limited

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial is testing a new medication called SCD-044 to see if it can help people with moderate to severe atopic dermatitis by reducing symptoms like itching and inflammation.

Eligibility Criteria

This trial is for adults over 18 with moderate to severe atopic dermatitis (eczema) that's been diagnosed for at least a year. It's not open to pregnant or nursing women, those planning pregnancy soon, or individuals with complications from diabetes like kidney issues, eye problems, or neuropathy.

Inclusion Criteria

I have had chronic atopic dermatitis for over a year.

I am 18 years old or older.

I have moderate to severe eczema.

Exclusion Criteria

I am not pregnant, nursing, or planning to become pregnant soon.

I have diabetes-related complications like kidney issues, eye problems, or nerve damage.

I have had or currently have uveitis.

Participant Groups

The study tests the effectiveness and safety of SCD-044 in three different doses compared to a placebo. Participants are randomly assigned to receive either the drug or placebo without knowing which one they're getting in this Phase II trial.

4Treatment groups

Active Control

Placebo Group

Group I: SCD-044 Tablets_Dose 1Active Control1 Intervention

SCD-044 Tablets of low dose (Dose 1) in subjects with moderate to severe atopic dermatitis.

Group II: SCD-044 Tablets_Dose 2Active Control1 Intervention

SCD-044 Tablets of intermediate dose (Dose 2) in subjects with moderate to severe atopic dermatitis.

Group III: SCD-044 Tablets_Dose 3Active Control1 Intervention

SCD-044 Tablets of high dose (Dose 3) in subjects with moderate to severe atopic dermatitis.

Group IV: Placebo of SCD-044 productPlacebo Group1 Intervention

Placebo tablet of SCD-044 product in subjects with moderate to severe atopic dermatitis.